Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-PSMA I&T for Biochemical Recurrent Prostate Cancer
NCT06220188Phase 2Recruiting
- Sponsor
- Medical University of Vienna
- Start
- Jan 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 PSMA I&T in prostate cancer (PCa), sponsored by Medical University of Vienna. Started Jan 2024; status: recruiting.
02
Drugs
lutetium Lu 177 PSMA I&T
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06220188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06220188.